Clinical trial · Interventional
MRI-guided Locoregional SBRT Prostate Program
MR-guided Brachytherapy and SBRT for Unfavorable Prostate Cancer
NCT07132073CI-TRIAL-00109763enrolling by invitationN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The implementation of Magnetic Resonance Image Guided Radiotherapy (MRgRT) into a Prostate Cancer Program will allow to reproduce the results obtained with state-of-the-art brachytherapy combined with EBRT with the added advantage of convenience.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brachytherapy + SBRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dose Escalation Phase
- description
- Brachytherapy + MR-guided SBRT
- interventionNames
- Radiation: Brachytherapy + SBRT
Primary outcomes (1)
- measure
- Biochemical relapse-free survival
- timeFrame
- 5-years
- description
- To achieve a 5-year biochemical relapse-free survival of 85%.
Secondary outcomes (1)
- measure
- Adverse Events
- timeFrame
- 5-years
- description
- To decrease urinary grade 3 or greater toxicity below 5% and rectal grade 3 or greater toxicity below 2%.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with unfavorable intermediate, high and very high risk PCa as per the NCCN stratification criteria . * Suboptimal candidates for high-dose therapy such as elderly, frail patients or patients with large volume glands (i.e, \>60cm3) or extensive TURP in the prior 6-12 months should be considered cautionary indications. * Patients with low risk of nodal spread may be treated on a MRI-guided local SBRT program. Exclusion Criteria: * No prior radiation therapy to the target areas * Patient able to undergo a MRI exam
References
Publications (0)
Data not yet available
No reference posted for this study.